TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: SURV1VE-Trial - Sustained Inflation and Chest Compression Versus 3:1 Chest Compression to Ventilation Ratio During Cardiopulmonary Resuscitation of Asphyxiated Newborns: A Randomized Controlled Trial
Brief Summary: Research question In newborn infants requiring CPR, does CC superimposed by sustained inflation compared to 3:1 compression to ventilation ratio improves return of spontaneous circulation?

Overall objective: CC superimposed by sustained inflation will improve short- and long-term outcomes in preterm (\>28 weeks or older) and term newborns.

Hypothesis to be tested Primary hypothesis: By using CC superimposed by sustained inflation (CC+SI) during CPR the time needed to achieve return of spontaneous circulation (ROSC) compared to the current 3:1 compression to ventilation (C:V) will be reduced in asphyxiated newborns.


Options:
A: Arm Label: "SI group"; Type: EXPERIMENTAL; Interventions: Procedure: SI group | Arm Label: IPPV group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: "IPPV group" | Intervention Type: PROCEDURE; Name: "IPPV group"; Assigned to Arm(s): IPPV group | Intervention Type: PROCEDURE; Name: SI group; Assigned to Arm(s): "SI group"
B: Arm Label: Control Arm-Standard of care; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard of Care | Arm Label: Sustained Intervention; Type: EXPERIMENTAL; Interventions: Procedure: Sustained Inflation | Intervention Type: PROCEDURE; Name: Sustained Inflation; Assigned to Arm(s): Sustained Intervention | Intervention Type: PROCEDURE; Name: Standard of Care; Assigned to Arm(s): Control Arm-Standard of care
C: Arm Label: SI+CC; Type: EXPERIMENTAL; Interventions: Procedure: CC+SI | Arm Label: 3:1 CPR; Type: ACTIVE_COMPARATOR; Interventions: Procedure: 3:1 CPR | Intervention Type: PROCEDURE; Name: CC+SI; Assigned to Arm(s): SI+CC | Intervention Type: PROCEDURE; Name: 3:1 CPR; Assigned to Arm(s): 3:1 CPR
D: Arm Label: Intervention (CC+SI); Type: EXPERIMENTAL; Interventions: Procedure: CC+SI | Arm Label: Control (3:1 C:V); Type: ACTIVE_COMPARATOR; Interventions: Procedure: 3:1 C:V | Intervention Type: PROCEDURE; Name: CC+SI; Assigned to Arm(s): Intervention (CC+SI) | Intervention Type: PROCEDURE; Name: 3:1 C:V; Assigned to Arm(s): Control (3:1 C:V)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Randomised, Open Label Study of Neoadjuvant Dabrafenib, Trametinib and / or Pembrolizumab in BRAF V600 Mutant Resectable Stage IIIB/C Melanoma
Brief Summary: This study aims to determine which of 3 drug combinations best reduces the size of tumour prior to surgery for advanced melanoma and prevents the recurrence of melanoma after surgery.


Options:
A: Arm Label: Sequential D + T, THEN Pembrolizumab; Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Drug: Trametinib, Drug: Pembrolizumab | Arm Label: Concurrent D + T AND Pembrolizumab; Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Drug: Trametinib, Drug: Pembrolizumab | Arm Label: Pembrolizumab ONLY; Type: EXPERIMENTAL; Interventions: Drug: Pembrolizumab | Intervention Type: DRUG; Name: Dabrafenib; Assigned to Arm(s): Concurrent D + T AND Pembrolizumab, Sequential D + T, THEN Pembrolizumab | Intervention Type: DRUG; Name: Trametinib; Assigned to Arm(s): Concurrent D + T AND Pembrolizumab, Sequential D + T, THEN Pembrolizumab | Intervention Type: DRUG; Name: Pembrolizumab; Assigned to Arm(s): Concurrent D + T AND Pembrolizumab, Pembrolizumab ONLY, Sequential D + T, THEN Pembrolizumab
B: Arm Label: Vemurafenib, pill, twice daily; Type: EXPERIMENTAL; Interventions: Drug: Vemurafenib, Drug: Cobimetinib | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): Vemurafenib, pill, twice daily | Intervention Type: DRUG; Name: Cobimetinib; Assigned to Arm(s): Vemurafenib, pill, twice daily
C: Arm Label: Arm 1: neoadjuvant + surgery; Type: EXPERIMENTAL; Interventions: Drug: L19IL2 + L19TNF, Procedure: Surgery | Arm Label: Arm 2: surgery alone; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgery | Intervention Type: DRUG; Name: L19IL2 + L19TNF; Assigned to Arm(s): Arm 1: neoadjuvant + surgery | Intervention Type: PROCEDURE; Name: Surgery; Assigned to Arm(s): Arm 1: neoadjuvant + surgery, Arm 2: surgery alone
D: Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgery of the tumor, Drug: Infusion with ipilimumab 3 mg/kg q3wks, Drug: Infusion with nivolumab 1 mg/kg q3wks | Arm Label: Arm B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgery of the tumor, Drug: Infusion with ipilimumab 3 mg/kg q3wks, Drug: Infusion with nivolumab 1 mg/kg q3wks | Intervention Type: PROCEDURE; Name: Surgery of the tumor; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Infusion with ipilimumab 3 mg/kg q3wks; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Infusion with nivolumab 1 mg/kg q3wks; Assigned to Arm(s): Arm A, Arm B

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Randomised, Open Label Study of Neoadjuvant Dabrafenib, Trametinib and / or Pembrolizumab in BRAF V600 Mutant Resectable Stage IIIB/C Melanoma
Brief Summary: This study aims to determine which of 3 drug combinations best reduces the size of tumour prior to surgery for advanced melanoma and prevents the recurrence of melanoma after surgery.


Options:
A: Arm Label: Single arm of ipilimumab and fotemustine; Type: EXPERIMENTAL; Interventions: Drug: Ipilimumab and Fotemustine | Intervention Type: DRUG; Name: Ipilimumab and Fotemustine; Assigned to Arm(s): Single arm of ipilimumab and fotemustine
B: Arm Label: Single Arm; Type: EXPERIMENTAL; Interventions: Drug: GSK2118436 | Intervention Type: DRUG; Name: GSK2118436; Assigned to Arm(s): Single Arm
C: Arm Label: Sequential D + T, THEN Pembrolizumab; Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Drug: Trametinib, Drug: Pembrolizumab | Arm Label: Concurrent D + T AND Pembrolizumab; Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Drug: Trametinib, Drug: Pembrolizumab | Arm Label: Pembrolizumab ONLY; Type: EXPERIMENTAL; Interventions: Drug: Pembrolizumab | Intervention Type: DRUG; Name: Dabrafenib; Assigned to Arm(s): Concurrent D + T AND Pembrolizumab, Sequential D + T, THEN Pembrolizumab | Intervention Type: DRUG; Name: Trametinib; Assigned to Arm(s): Concurrent D + T AND Pembrolizumab, Sequential D + T, THEN Pembrolizumab | Intervention Type: DRUG; Name: Pembrolizumab; Assigned to Arm(s): Concurrent D + T AND Pembrolizumab, Pembrolizumab ONLY, Sequential D + T, THEN Pembrolizumab
D: Arm Label: GSK2118436; Type: EXPERIMENTAL; Interventions: Drug: GSK2118436 | Arm Label: Dacarbazine (DTIC); Type: ACTIVE_COMPARATOR; Interventions: Drug: Dacarbazine (DTIC) | Arm Label: Crossover; Type: EXPERIMENTAL; Interventions: Drug: GSK2118436 | Intervention Type: DRUG; Name: GSK2118436; Assigned to Arm(s): Crossover, GSK2118436 | Intervention Type: DRUG; Name: Dacarbazine (DTIC); Assigned to Arm(s): Dacarbazine (DTIC)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline Augmentation of Patch Outcomes in Heavy Drinkers' Smoking Cessation
Brief Summary: The purpose of this study is to learn if the combination of a study drug and patch is more effective in helping heavy drinkers stop smoking than just the patch alone The study drug, varenicline, has been approved by the Food and Drug Administration (FDA) to help people stop smoking, but it is not known if the addition of varenicline to standard smoking cessation treatment with nicotine patches will help people stop smoking who are regular, frequent drinkers. This study is being done because cigarette smoking is the number one preventable cause of death and disease in the United States.


Options:
A: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
B: Arm Label: Augmented Treatment; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Behavioral: Behavioral Counseling Sessions, Drug: NicodermCQ | Arm Label: Standard Treatment w/ placebo; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral Counseling Sessions, Drug: NicodermCQ, Drug: Placebo | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): Augmented Treatment | Intervention Type: BEHAVIORAL; Name: Behavioral Counseling Sessions; Assigned to Arm(s): Augmented Treatment, Standard Treatment w/ placebo | Intervention Type: DRUG; Name: NicodermCQ; Assigned to Arm(s): Augmented Treatment, Standard Treatment w/ placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Standard Treatment w/ placebo
C: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
D: Arm Label: Electronic cigarette condition; Type: EXPERIMENTAL; Interventions: Drug: Electronic cigarette with nicotine (ECwN) plus placebo tablets of varenicline | Arm Label: Varenicline condition; Type: ACTIVE_COMPARATOR; Interventions: Drug: Electronic cigarette without nicotine (ECwN) plus active varenicline tablets | Arm Label: Placebo condition; Type: PLACEBO_COMPARATOR; Interventions: Drug: Electronic cigarette without nicotine (ECwoN) plus placebo tablets of varenicline | Intervention Type: DRUG; Name: Electronic cigarette without nicotine (ECwN) plus active varenicline tablets; Assigned to Arm(s): Varenicline condition | Intervention Type: DRUG; Name: Electronic cigarette without nicotine (ECwoN) plus placebo tablets of varenicline; Assigned to Arm(s): Placebo condition | Intervention Type: DRUG; Name: Electronic cigarette with nicotine (ECwN) plus placebo tablets of varenicline; Assigned to Arm(s): Electronic cigarette condition

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness and Cost-effectiveness of Telemedicine for Heart Failure: The Danish "TeleCare North" Pragmatic Randomized Trial
Brief Summary: There are two main aims in this study. The first objective is to evaluate whether a particular telehealth solution, in addition to standard treatment and care, lead to a significant decrease in the mortality and an increase in health related quality of life for patients suffering from Heart Failure that may benefit from telehealth compared with only standard treatment and care. The second objective is to examine the additional costs of the telehealth solution and assess whether this solution is a cost-effective way to care for patients with Heart Failure across patients and municipality districts.

It is hypothesized that telehealth care will increase patients quality adjusted life years compared to usual practice, since no difference in mortality and a higher health related quality of life is expected. Furthermore, it is hoped that there will be a 30% reduction in the number of admissions and readmissions to hospitals and a 30% reduction in the number of outpatient visits resulting in fewer costs for hospitals. However, it is uncertain as to whether these savings are offset by other costs such as more visits to general practitioners, community care or the implementation costs.


Options:
A: Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention Group I; Type: EXPERIMENTAL; Interventions: Behavioral: self-regulation | Intervention Type: BEHAVIORAL; Name: self-regulation; Assigned to Arm(s): Intervention Group I
B: Arm Label: Telemedicine; Type: ACTIVE_COMPARATOR; Interventions: Device: Telemedicine | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Telemedicine; Assigned to Arm(s): Telemedicine
C: Arm Label: Control group (Group A); Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Arm Label: Intervention group (Group B); Type: OTHER; Interventions: Other: Home-based telehealth program, Other: Home-based rehabilitation, Other: Usual care | Intervention Type: OTHER; Name: Home-based telehealth program; Assigned to Arm(s): Intervention group (Group B) | Intervention Type: OTHER; Name: Home-based rehabilitation; Assigned to Arm(s): Intervention group (Group B) | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Control group (Group A), Intervention group (Group B)
D: Arm Label: telerehabilitation group; Type: EXPERIMENTAL; Interventions: Other: home-based telerehabilitation | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: home-based telerehabilitation; Assigned to Arm(s): telerehabilitation group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT)
Brief Summary: The purpose of this research is to determine if an investigational new drug solution called Prismocitrate 18 lengthens extracorporeal circuit life in patients treated with continuous renal replacement therapy (CRRT). Patients who receive CRRT treatment with Prismocitrate 18 as the anticoagulant will be compared to patients who receive CRRT treatment with no anticoagulation.


Options:
A: Arm Label: Prismocitrate 18; Type: EXPERIMENTAL; Interventions: Drug: Prismocitrate 18 | Arm Label: No Regional Anticoagulation of CRRT Circuit; Type: ACTIVE_COMPARATOR; Interventions: Other: No Anticoagulation | Intervention Type: DRUG; Name: Prismocitrate 18; Assigned to Arm(s): Prismocitrate 18 | Intervention Type: OTHER; Name: No Anticoagulation; Assigned to Arm(s): No Regional Anticoagulation of CRRT Circuit
B: Arm Label: heparin anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin | Arm Label: citrate anticoagulation; Type: EXPERIMENTAL; Interventions: Drug: Citrate | Intervention Type: DRUG; Name: Heparin; Assigned to Arm(s): heparin anticoagulation | Intervention Type: DRUG; Name: Citrate; Assigned to Arm(s): citrate anticoagulation
C: Arm Label: CVVHD-ST150; Type: EXPERIMENTAL; Interventions: Other: CVVHD | Arm Label: CVVH-ST150; Type: ACTIVE_COMPARATOR; Interventions: Other: CVVH | Intervention Type: OTHER; Name: CVVHD; Assigned to Arm(s): CVVHD-ST150 | Intervention Type: OTHER; Name: CVVH; Assigned to Arm(s): CVVH-ST150
D: Arm Label: RCA Group; Type: EXPERIMENTAL; Interventions: Drug: Anticoagulation to prevent clotting of the extracorporeal circuit. (regional citrate anticoagulation) | Arm Label: Heparin group; Type: EXPERIMENTAL; Interventions: Drug: Anticoagulation to prevent clotting of the extracorporeal circuit (Unfractionated heparin) | Intervention Type: DRUG; Name: Anticoagulation to prevent clotting of the extracorporeal circuit. (regional citrate anticoagulation); Assigned to Arm(s): RCA Group | Intervention Type: DRUG; Name: Anticoagulation to prevent clotting of the extracorporeal circuit (Unfractionated heparin); Assigned to Arm(s): Heparin group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT)
Brief Summary: The purpose of this research is to determine if an investigational new drug solution called Prismocitrate 18 lengthens extracorporeal circuit life in patients treated with continuous renal replacement therapy (CRRT). Patients who receive CRRT treatment with Prismocitrate 18 as the anticoagulant will be compared to patients who receive CRRT treatment with no anticoagulation.


Options:
A: Arm Label: Prismocitrate 18; Type: EXPERIMENTAL; Interventions: Drug: Prismocitrate 18 | Arm Label: No Regional Anticoagulation of CRRT Circuit; Type: ACTIVE_COMPARATOR; Interventions: Other: No Anticoagulation | Intervention Type: DRUG; Name: Prismocitrate 18; Assigned to Arm(s): Prismocitrate 18 | Intervention Type: OTHER; Name: No Anticoagulation; Assigned to Arm(s): No Regional Anticoagulation of CRRT Circuit
B: Arm Label: PR1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Argatroban | Arm Label: PR2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lepirudin | Intervention Type: DRUG; Name: Argatroban; Assigned to Arm(s): PR1 | Intervention Type: DRUG; Name: Lepirudin; Assigned to Arm(s): PR2
C: Arm Label: M100; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anticoagulation with nafamostat mesilate | Arm Label: HF1000; Type: EXPERIMENTAL; Interventions: Drug: Anticoagulation with nafamostat mesilate | Intervention Type: DRUG; Name: Anticoagulation with nafamostat mesilate; Assigned to Arm(s): HF1000, M100
D: Arm Label: heparin anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin | Arm Label: citrate anticoagulation; Type: EXPERIMENTAL; Interventions: Drug: Citrate | Intervention Type: DRUG; Name: Heparin; Assigned to Arm(s): heparin anticoagulation | Intervention Type: DRUG; Name: Citrate; Assigned to Arm(s): citrate anticoagulation

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT)
Brief Summary: The purpose of this research is to determine if an investigational new drug solution called Prismocitrate 18 lengthens extracorporeal circuit life in patients treated with continuous renal replacement therapy (CRRT). Patients who receive CRRT treatment with Prismocitrate 18 as the anticoagulant will be compared to patients who receive CRRT treatment with no anticoagulation.


Options:
A: Arm Label: High citrate group; Type: EXPERIMENTAL; Interventions: Drug: Citrate | Arm Label: Low citrate group; Type: EXPERIMENTAL; Interventions: Drug: Citrate | Intervention Type: DRUG; Name: Citrate; Assigned to Arm(s): High citrate group, Low citrate group
B: Arm Label: PR1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Argatroban | Arm Label: PR2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lepirudin | Intervention Type: DRUG; Name: Argatroban; Assigned to Arm(s): PR1 | Intervention Type: DRUG; Name: Lepirudin; Assigned to Arm(s): PR2
C: Arm Label: Heparin lock; Type: PLACEBO_COMPARATOR; Interventions: Drug: unfractionated heparin | Arm Label: Citrate lock; Type: EXPERIMENTAL; Interventions: Drug: Citrate 4% | Intervention Type: DRUG; Name: Citrate 4%; Assigned to Arm(s): Citrate lock | Intervention Type: DRUG; Name: unfractionated heparin; Assigned to Arm(s): Heparin lock
D: Arm Label: Prismocitrate 18; Type: EXPERIMENTAL; Interventions: Drug: Prismocitrate 18 | Arm Label: No Regional Anticoagulation of CRRT Circuit; Type: ACTIVE_COMPARATOR; Interventions: Other: No Anticoagulation | Intervention Type: DRUG; Name: Prismocitrate 18; Assigned to Arm(s): Prismocitrate 18 | Intervention Type: OTHER; Name: No Anticoagulation; Assigned to Arm(s): No Regional Anticoagulation of CRRT Circuit

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nursing Home Team-Care Deprescribing Study
Brief Summary: This is a multi-centre study in Singapore nursing homes, investigating the factors that affecting deprescribing, and if a team-care based deprescribing standard practice gives superior health and pharmacoeconomic outcomes over current medication review practice.


Options:
A: Arm Label: naive Deprescribing arm; Type: EXPERIMENTAL; Interventions: Other: Team-care deprescribing with deprescribing guide | Arm Label: naive Wait-list Control arm; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: non-naive Deprescribing arm; Type: EXPERIMENTAL; Interventions: Other: Team-care deprescribing with deprescribing guide | Arm Label: non-naive Wait-list Control arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Team-care deprescribing with deprescribing guide; Assigned to Arm(s): naive Deprescribing arm, non-naive Deprescribing arm
B: Intervention Type: BEHAVIORAL; Name: Opinion leader generated and endorsed evidence summaries; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Pharmacist intervention; Assigned to Arm(s): N/A
D: Arm Label: Pharmacist service,; Type: ACTIVE_COMPARATOR; Interventions: Other: Pharmacist service | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Pharmacist service; Assigned to Arm(s): Pharmacist service,

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nursing Home Team-Care Deprescribing Study
Brief Summary: This is a multi-centre study in Singapore nursing homes, investigating the factors that affecting deprescribing, and if a team-care based deprescribing standard practice gives superior health and pharmacoeconomic outcomes over current medication review practice.


Options:
A: Intervention Type: BEHAVIORAL; Name: Self-management of chronic illness; Assigned to Arm(s): N/A
B: Arm Label: Multidisciplinary medication review; Type: EXPERIMENTAL; Interventions: Procedure: Multidisciplinary medication review | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Multidisciplinary medication review; Assigned to Arm(s): Multidisciplinary medication review
C: Arm Label: Comprehensive drug review; Type: EXPERIMENTAL; Interventions: Other: Comprehensive drug review | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Comprehensive drug review; Assigned to Arm(s): Comprehensive drug review
D: Arm Label: naive Deprescribing arm; Type: EXPERIMENTAL; Interventions: Other: Team-care deprescribing with deprescribing guide | Arm Label: naive Wait-list Control arm; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: non-naive Deprescribing arm; Type: EXPERIMENTAL; Interventions: Other: Team-care deprescribing with deprescribing guide | Arm Label: non-naive Wait-list Control arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Team-care deprescribing with deprescribing guide; Assigned to Arm(s): naive Deprescribing arm, non-naive Deprescribing arm

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: COMRADE: Collaborative Care Management for Distress and Depression in Rural Diabetes
Brief Summary: The study will implement and evaluate, using a pragmatic comparative effectiveness trial, a unique collaborative, stepped-care intervention for patients with uncontrolled Type 2 diabetes and co-morbid distress and/or depression.


Options:
A: Arm Label: Medication therapy management; Type: EXPERIMENTAL; Interventions: Other: Medication therapy management | Intervention Type: OTHER; Name: Medication therapy management; Assigned to Arm(s): Medication therapy management
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Full drug coverage | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual coverage | Intervention Type: OTHER; Name: Full drug coverage; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Usual coverage; Assigned to Arm(s): 2
C: Arm Label: Post-discharge phone call; Type: N/A; Interventions: N/A | Arm Label: Usual care (no phone call); Type: N/A; Interventions: N/A
D: Arm Label: Integrated Behavioral Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Integrated Behavioral Care | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Integrated Behavioral Care; Assigned to Arm(s): Integrated Behavioral Intervention

Answer: D